Erythropoietin (EPO) promotes neuronal survival after hypoxia and other met
abolic insults by largely unknown mechanisms. Apoptosis and necrosis have b
een proposed as mechanisms of cellular demise, and either could be the targ
et of actions of EPO. This study evaluates whether antiapoptotic mechanisms
can account for the neuroprotective actions of EPO, Systemic administratio
n of EPO (5,000 units/kg of body weight, i.p.) after middle-cerebral artery
occlusion in rats dramatically reduces the volume of infarction 24 h later
, in concert with an almost complete reduction in the number of terminal de
oxynucleotidyltransferase-mediated dUTP nick-end labeling of neurons within
the ischemic penumbra. In both pure and mixed neuronal cultures, EPO (0.1-
10 units/ml) also inhibits apoptosis induced by serum deprivation or kainic
acid exposure. Protection requires pretreatment, consistent with the induc
tion of a gene expression program, and is sustained for 3 days without the
continued presence of EPO, EPO (0.3 units/ml) also protects hippocampal neu
rons against hypoxia-induced neuronal death through activation of extracell
ular signal-regulated kinases and protein kinase Akt-1/protein kinase B, Th
e action of EPO is not limited to directly promoting cell survival, as EPO
is trophic but not mitogenic in cultured neuronal cells. These data suggest
that inhibition of neuronal apoptosis underlies short latency protective e
ffects of EPO after cerebral ischemia and other brain injuries. The neurotr
ophic actions suggest there may be longer-latency effects as well. Evaluati
on of EPO, a compound established as clinically safe, as neuroprotective th
erapy in acute brain injury is further supported.